Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | RYR2 | Q92736 | 4/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | S100A4 | P26447 | 1/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31001736 | 0.87 | ALDH1A1 (0.48) | HPGDALDH1A1MEN1GAAKMT2A | |
| SCHEMBL255970 | 0.87 | ALDH1A1 (0.48) | HPGDALDH1A1MEN1GAAKMT2A | |
| SCHEMBL13864396 | 0.80 | HPGD (0.57) | HPGDALDH1A1MEN1GAAKMT2A | |
| SCHEMBL23813034 | 0.79 | ALDH1A1 (0.43) | HPGDALDH1A1MEN1GAAKMT2A | |
| SCHEMBL21629350 | 0.79 | ALDH1A1 (0.43) | HPGDALDH1A1MEN1GAAKMT2A | |
| SCHEMBL1267700 | 0.76 | RYR2 (0.50) | HPGDALDH1A1MEN1GAAKMT2A | |
| SCHEMBL30118876 | 0.76 | RYR2 (0.50) | HPGDALDH1A1MEN1GAAKMT2A | |
| SCHEMBL130168 | 0.76 | RYR2 (0.50) | HPGDALDH1A1MEN1GAAKMT2A | |
| SCHEMBL13864438 | 0.76 | HPGD (0.40) | HPGDALDH1A1MEN1GAAKMT2A | |
| SCHEMBL542070 | 0.75 | TSHR (0.52) | HPGDALDH1A1MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1478634-A4 | FURANONE DERIVATIVES | GALILEO PHARMACEUTICALS INC (US) | 2006-02-01 | — | — | EP | claimed |
| EP-1478634-A1 | FURANONE DERIVATIVES | Galileo Pharmaceuticals, Inc. (US) | 2004-11-24 | — | — | EP | claimed |
| US-6667330-B2 | Cytoprotective; neuroinflammation and neurodegenerative disorders; oxidative stress related conditions | GALILEO PHARMACEUTICALS, INC. | 2003-12-23 | — | — | US | claimed |
| US-20030176361-A1 | Furanone derivatives | MONSANTO TECHNOLOGY LLC | 2003-09-18 | — | — | US | claimed |
| WO-2003064403-A1 | FURANONE DERIVATIVES | GALILEO LABORATORIES, INC. (US) | 2003-08-07 | — | — | WO | claimed |
| US-7985771-B2 | Skin disorders; aging resistance | MONSANTO TECHNOLOGY LLC (US) | 2011-07-26 | — | — | US | disclosed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-20070232538-A1 | Uses of polypeptides | TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) | 2007-10-04 | — | — | US | disclosed |
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-25 | — | — | US | disclosed |
| US-7138533-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-21 | — | — | US | disclosed |
| US-7132547-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-07 | — | — | US | disclosed |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ISHIHARA YUJI | 2006-09-21 | — | — | US | disclosed |
| WO-1996024344-A1 | USE OF RETINOIDS TO LOWER PLASMA LEVELS OF LIPOPROTEIN (a) | WARNER-LAMBERT COMPANY (US) | 1996-08-15 | — | — | WO | disclosed |
| EP-0350846-B1 | Condensed heterocyclic compounds and their use in therapy | HOFFMANN LA ROCHE (CH) | 1995-10-11 | — | — | EP | disclosed |
| US-5420273-A | Skin disorders and antitumor agents | HOFFMAN-LA ROCHE INC. (US) | 1995-05-30 | — | — | US | disclosed |
| US-5300522-A | Treating inflammatory, allergic, rheumatic, immunological disorders | HOFFMANN-LA ROCHE INC. (US) | 1994-04-05 | — | — | US | disclosed |
| EP-0567090-A2 | Benzoxazepine derivatives as cholinesterase inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-10-27 | — | — | EP | disclosed |
| US-5164387-A | Antitumor agents, skin disorders, antiinflammatory agents | HOFFMANN-LAROCHE INC. (US) | 1992-11-17 | — | — | US | disclosed |
| US-5037825-A | Useful In The Treatment Of Neoplasms, Dermatoses And Aging Of The Skin | HOFFMANN-LA ROCHE INC. (US) | 1991-08-06 | — | — | US | disclosed |
| EP-0350846-A2 | Condensed heterocyclic compounds and their use in therapy | F. HOFFMANN-LA ROCHE AG (CH) | 1990-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | ACHE, BCHE, CHAT | HPGD 383/4885ALDH1A1 346/4885MEN1 2903/4885 |
| US-20030176361-A1 | Furanone derivatives | HSPA9, HSF1, IL1B | HPGD 160/4885ALDH1A1 903/4885MEN1 3577/4885 |
| US-20070232538-A1 | Uses of polypeptides | NPSR1, SCTR, GRPR | HPGD 4273/4885ALDH1A1 3946/4885MEN1 4302/4885 |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, ACE | HPGD 267/4885ALDH1A1 212/4885MEN1 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.